PreClinical_New - IGCPharma

Preclinical:
The Research Powering IGC-AD1

IGC-AD1 is built on preclinical research conducted on its active pharmaceutical ingredients (APIs). At low concentrations, the APIs showed promising results in both in vitro and in vivo efficacy assays related to the hallmarks of Alzheimer’s disease.

Early Lab Discoveries
That Inspire Hope

Preclinical studies laid the foundation for IGC-AD1 by testing its dual active ingredients in Alzheimer’s disease cells and mice models.

Preclinical Spatial Memory Study in APP/PS1 Transgenic Mice

APP/PS1 Transgenic mice treated with IGC-AD1 API showed about a 50% reduction in both latencies to escape and number of errors, compared to untreated controls.

Reduces Key
Alzheimer’s Features

IGC-AD1 API preserves Aβ40 Monomers and Inhibits Aggregation
as Assessed by ThT Assay.

Mitochondrial Respiratory Activity in IGC-AD1
API-Treated APP/PS1 Mouse Model

Treatment with IGC-AD1 API led to improved and restored mitochondrial function in the hippocampus and cortex of APP/PS1 Transgenic Mouse Model, two regions affected in Alzheimer’s disease.

The science behind IGC-AD1: Early indicators that matter
for Alzheimer’s Disease research

The API in IGC-AD1 reduces Aβ40 peptide production and Aβ42 aggregation in Alzheimer’s cell lines.

Representation of Cao et al., 2014

APP Levels

The APIs in IGC-AD1 did not reduce Amyloid Precursor Protein (APP) levels in Alzheimer’s cell lines. APP modulates cell growth, motility, and survival; it is cut to create small fragments such as the Aβ peptide that eventually deposit as plaque.

Spatial Memory

Spatial Memory Study in APP/PS1 Transgenic Mice
In the Radial Arm Water Maze (RAWM) test, IGC-AD1 API treatment resulted in over a 50% reduction in both latencies to escape and number of errors in APP/PS1 transgenic mice, compared to untreated controls.

Explore Our Development Path

Phase I:
Clinical trial

The study involved participants with mild-to-moderate Alzheimer’s Disease to evaluate the safety and tolerability of IGC-AD1.

Phase II:
CALMA

CALMA is a multicenter Phase 2 clinical trial designed to evaluate the safety and efficacy of IGC-AD1 for treating agitation associated with Alzheimer’s dementia.

Preclinical: The Research Powering IGC-AD1